HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.

Abstract
Infliximab (INF), a tumor necrosis factor-alpha (TNF-alpha) inhibitor, is an effective drug for patients with rheumatoid arthritis (RA). However, some patients receive no clinical benefit, or the agents gradually lose their effect. Five sessions of high-throughput leukocytapheresis (LCAP) were given at a frequency of once a week using a Cellsorba CS-180S to four patients with a reduced response to INF. The clinical response to LCAP was evaluated using the 28-joint disease activity score with C-reactive protein (DAS28-CRP) and with the erythrocyte sedimentation rate (DAS28-ESR). DAS28-CRP decreased significantly from 5.8 +/- 0.6 before LCAP to 3.9 +/- 0.7 (P = 0.0182) at 1-2 weeks after completion of five sessions of LCAP, and DAS28-ESR decreased significantly from 6.4 +/- 0.6 to 4.6 +/- 0.5 (P = 0.0267). Moreover, all patients had a moderate response according to the European League Against Rheumatism (EULAR) response criteria. The effect of LCAP continued for at least 6 months after its completion in all patients, with no changes in any of their concomitant drugs, and the effect was maintained for at least 1 year in three of the four patients. These results indicate that LCAP is a useful treatment for RA patients with a reduced response to INF.
AuthorsYukinao Sakai, Saori Sakai, Tomoyuki Otsuka, Dai Ohno, Tsuneo Murasawa, Kazuo Munakata, Kyoichi Mizuno
JournalTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 13 Issue 3 Pg. 179-85 (Jun 2009) ISSN: 1744-9987 [Electronic] Australia
PMID19527463 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • C-Reactive Protein
  • Infliximab
Topics
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (therapy)
  • Blood Sedimentation
  • C-Reactive Protein (metabolism)
  • Female
  • Humans
  • Infliximab
  • Leukapheresis (methods)
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: